Halozyme Therapeutics (HALO) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 3[1].
Trial NCT06689085[3] evaluates Testosterone enanthate in Hypogonadism, Male with a target enrollment of 100 participants.
HALO has 3 Form 4 insider filings recorded at the SEC in the past 30 days[4].